clinical trial · NCT04085653
Managed Access Programs for BYL719, Alpelisib
PIK3CA-Related Overgrowth Spectrum (PROS)Breast Canceralpelisib
brief summary
The purpose of this registration is to list Managed Access Programs (MAPs) related to BYL719, Alpelisib
started
—
primary completion
—
completion
—
last updated
Apr 14, 2026
detailed description
CBYL719F12001M - Available - Managed Access Program (MAP) Cohort to provide access to Alpelisib (BYL719) for patients with PIK3CA-Related Overgrowth Spectrum (PROS)
CBYL719C2001M - Available - Managed Access Program (MAP) Cohort to provide access to alpelisib (BYL719) for patients with HR-positive, HER2-negative advanced breast cancer with mutated phosphoinositide 3-kinase who progressed on or after AI treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol